Judith Lightfoot, DO
Infectious Disease · Stratford, NJNPI 1922046630
Payments from drug & device makers
Across 14 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GRT US Holding, Inc.$186
- Viiv Healthcare Company$100
- Novo Nordisk$16
- Gilead$15
- Johnson & Johnson$13
What the payments were for
- Food & beverage$14544%
- Education$18656%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GRT US Holding, Inc. | 4 | $186 |
| Viiv Healthcare Company | 7 | $100 |
| Novo Nordisk | 1 | $16 |
| Gilead | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$331 in reported general payments places this provider in the 35th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 210 | $835,623 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 183 | $728,736 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 156 | $606,658 |
| JulucaDolutegravir/Rilpivirine | 63 | $215,823 |
| CabenuvaCabotegravir/Rilpivirine | 28 | $192,302 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 44 | $173,741 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $141,630 |
| DovatoDolutegravir Sodium/Lamivudine | 41 | $120,549 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 30 | $105,133 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $101,302 |
| TivicayDolutegravir Sodium | 47 | $101,026 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $89,905 |
| EdurantRilpivirine Hcl | 18 | $35,477 |
| OzempicSemaglutide | 36 | $33,066 |
| Isentress HdRaltegravir Potassium | 17 | $32,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Stribild, Descovy | $15 | $1,839,403484 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Cabenuva, Dovato, Tivicay | $100 | $1,236,358335 claims |
| Novo NordiskOzempic | $16 | $33,06636 claims |
| Johnson & JohnsonXarelto | $13 | $19,82237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Stratford
- Jihad SlimNewark$6.7M
- Ronald NahassHillsborough$6.1M
- Bindu BalaniHackensack$4.9M
- Suraj SaggarEnglewood$2.9M
- Christopher LucastiSomers Point$2.8M
- Edward LiuNeptune$2.6M
- Keith GottesdienerRahway$2.1M
- Amna YaqubFlemington$1.4M
- Shobha SwaminathanNewark$1.4M
- Mohamed RabbatPaterson$760K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.